Coherus BioSciences, Inc.

NasdaqGM:CHRS Stok Raporu

Piyasa değeri: US$94.6m

Coherus BioSciences Yönetim

Yönetim kriter kontrolleri 3/4

Coherus BioSciences CEO'su Denny Lanfear, Sep2010 tarihinde atandı, in görev süresi 14.17 yıldır. in toplam yıllık tazminatı $ 5.90M olup, şirket hissesi ve opsiyonları dahil olmak üzere 16.7% maaş ve 83.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.99% ine doğrudan sahiptir ve bu hisseler $ 937.64K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 3.3 yıldır.

Anahtar bilgiler

Denny Lanfear

İcra Kurulu Başkanı

US$5.9m

Toplam tazminat

CEO maaş yüzdesi16.7%
CEO görev süresi14.2yrs
CEO sahipliği1.0%
Yönetim ortalama görev süresi2.8yrs
Yönetim Kurulu ortalama görev süresi3.3yrs

Son yönetim güncellemeleri

Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

May 23
Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

Recent updates

Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%

Nov 06
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Sep 22
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Aug 13

Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Aug 07
Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

May 31

Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

May 23
Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Mar 21

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Feb 03
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Jan 17

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Dec 20
Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

May 13
The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3

Sep 19

Coherus: 2022 Is In Many Ways A Make Or Break Year

Aug 24

Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli

Aug 03

Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer

Jul 06

Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?

Jun 15
Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?

Coherus: Will Its Chinese Gambit Fail?

May 27

CEO Tazminat Analizi

Denny Lanfear'un ücretlendirmesi Coherus BioSciences'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$450k

Jun 30 2024n/an/a

-US$29m

Mar 31 2024n/an/a

-US$59m

Dec 31 2023US$6mUS$983k

-US$238m

Sep 30 2023n/an/a

-US$217m

Jun 30 2023n/an/a

-US$264m

Mar 31 2023n/an/a

-US$271m

Dec 31 2022US$7mUS$945k

-US$292m

Sep 30 2022n/an/a

-US$279m

Jun 30 2022n/an/a

-US$230m

Mar 31 2022n/an/a

-US$210m

Dec 31 2021US$9mUS$885k

-US$287m

Sep 30 2021n/an/a

-US$232m

Jun 30 2021n/an/a

-US$165m

Mar 31 2021n/an/a

-US$76m

Dec 31 2020US$7mUS$857k

US$132m

Sep 30 2020n/an/a

US$162m

Jun 30 2020n/an/a

US$181m

Mar 31 2020n/an/a

US$145m

Dec 31 2019US$5mUS$751k

US$90m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

-US$118m

Mar 31 2019n/an/a

-US$185m

Dec 31 2018US$4mUS$702k

-US$209m

Sep 30 2018n/an/a

-US$196m

Jun 30 2018n/an/a

-US$196m

Mar 31 2018n/an/a

-US$208m

Dec 31 2017US$3mUS$656k

-US$238m

Tazminat ve Piyasa: Denny 'nin toplam tazminatı ($USD 5.90M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 652.28K ).

Tazminat ve Kazançlar: Denny 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Denny Lanfear (69 yo)

14.2yrs

Görev süresi

US$5,897,924

Tazminat

Mr. Dennis M. Lanfear, also known as Denny, Co-founder, Chairman, Chief Executive Officer and President of Coherus Biosciences Inc. since September 2010. Mr. Lanfear serves as the President of Lanfear Capi...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Dennis Lanfear
Chairman14.2yrsUS$5.90m0.99%
$ 937.6k
Bryan McMichael
Former Interim CFO2.2yrsUS$1.07m0.023%
$ 21.7k
Paul Reider
Chief Commercial Officer3.8yrsUS$1.93m0.071%
$ 66.8k
Richard Hameister
Chief Technical Officer2.8yrsVeri yokVeri yok
Jami Taylor
Vice President of Investor Relationsno dataVeri yokVeri yok
Andy Rittenberg
Executive Vice President of General Counselless than a yearVeri yokVeri yok
Cheston Turbyfill
Vice President of Communicationsno dataVeri yokVeri yok
Scott Saywell
Executive Vice President of Corporate Development1.8yrsVeri yokVeri yok
Rebecca Sunshine
Chief Human Resources Officerno dataVeri yokVeri yok
Michael Chen
Senior Vice President of Commercial Analytics & Tradeno dataVeri yokVeri yok
Theresa Lavallee
Chief Development Officer & Chairman of Scientific Advisory Board2.8yrsVeri yokVeri yok
Rosh Dias
Chief Medical Officer2.7yrsVeri yokVeri yok

2.8yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim: CHRS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Dennis Lanfear
Chairman14.2yrsUS$5.90m0.99%
$ 937.6k
Theresa Lavallee
Chief Development Officer & Chairman of Scientific Advisory Board2.8yrsVeri yokVeri yok
Mats Wahlstrom
Lead Independent Director12.8yrsUS$228.69k0.087%
$ 82.1k
Mark Stolper
Independent Director3.8yrsUS$198.69k0.0076%
$ 7.2k
Ali Satvat
Independent Director10.5yrsUS$65.00k0%
$ 0
Lee Newcomer
Independent Director2.8yrsUS$186.19k0%
$ 0
James Daly
Member of Strategic Advisory Board1.2yrsVeri yokVeri yok
Charles Newton
Independent Director2.5yrsUS$188.69k0%
$ 0
Jill O'Donnell-Tormey
Independent Director2.5yrsUS$183.69k0%
$ 0
Kimberly Tzoumakas
Independent Director4.3yrsUS$193.69k0%
$ 0
Carl Ware
Member of Scientific Advisory Board3.3yrsVeri yokVeri yok
Thomas Graeber
Member of Scientific Advisory Board3.3yrsVeri yokVeri yok

3.3yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CHRS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).